Scholarlink

<p>Adolescent and early young adult (AeYA) cancer survivors (aged 15–25 years) face elevated risks of depression following remission. Emerging evidence suggests that brain metabolic vulnerability, detectable via 18-F FDG PET/CT, may serve as a sentinel biomarker for latent depression risk. To investigate this hypothesis, we conducted a multicenter longitudinal study in two independent cohorts (n = 923 discovery, n = 518 validation) in which participants underwent sequential PET/CT scans and were followed for 3 years (mean follow-up: 29.58 ± 10.01 months). Reduced SUVmean values in the ventral prefrontal cortex, hippocampus, and amygdala predominantly predicted future depression onset after adjusting for clinical, psychosocial, and treatment-related confounders. A radiomic nomogram integrating these metabolic parameters demonstrated robust predictive accuracy (C-index: 0.91 discovery, 0.88 validation). By identifying neurobiological susceptibility years before symptom emergence, this study points to 18-F FDG PET/CT as a clinically actionable tool for preemptive depression risk stratification in AeYA survivors, thus repurposing 18F-FDG PET/CT from tumor management surveillance to preemptive depression risk screening.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brain metabolic vulnerability in 18-F FDG PET/CT predict future depression risk in young cancer survivors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月31日

查看全文
  • Nianqi Liu,
  • Jingjie Sun,
  • Yongluo Jiang,
  • Shenrui Bai,
  • Youlong Wang,
  • Jun Lu,
  • Weidong Wang,
  • Pengfei Zhu,
  • Guangmin Jian,
  • Jiling Zeng,
  • Xinjia Wang,
  • Jianwen Chen,
  • Yifei Ma

摘要

Adolescent and early young adult (AeYA) cancer survivors (aged 15–25 years) face elevated risks of depression following remission. Emerging evidence suggests that brain metabolic vulnerability, detectable via 18-F FDG PET/CT, may serve as a sentinel biomarker for latent depression risk. To investigate this hypothesis, we conducted a multicenter longitudinal study in two independent cohorts (n = 923 discovery, n = 518 validation) in which participants underwent sequential PET/CT scans and were followed for 3 years (mean follow-up: 29.58 ± 10.01 months). Reduced SUVmean values in the ventral prefrontal cortex, hippocampus, and amygdala predominantly predicted future depression onset after adjusting for clinical, psychosocial, and treatment-related confounders. A radiomic nomogram integrating these metabolic parameters demonstrated robust predictive accuracy (C-index: 0.91 discovery, 0.88 validation). By identifying neurobiological susceptibility years before symptom emergence, this study points to 18-F FDG PET/CT as a clinically actionable tool for preemptive depression risk stratification in AeYA survivors, thus repurposing 18F-FDG PET/CT from tumor management surveillance to preemptive depression risk screening.